Exscientia plc (EXAI) NASDAQ
4.84
+(+%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Exscientia plc
Address
The SchrOedinger Building
Oxford, OX4 4GE
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 18 6581 8941
Website
Sector
Healthcare
Industry
Biotechnology
Employees
483
First IPO Date
October 01, 2021
Key Executives
| Name | Title | Pay | Year Born |
| David Hallett | Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer & Executive Director | 0 | 1969 |
| Ben R. Taylor | Chief Financial Officer, Chief Strategy Officer & Executive Director | 558,080 | 1977 |
| Marie-Louise Helena Fjallskog | Interim Chief Medical Officer & Clinical Development Lead | 0 | 1964 |
| Dan Ireland | Executive Vice President of Legal & Company Secretary | 0 | N/A |
| Nikolaus Krall | Executive Vice President of Precision Medicine | 0 | N/A |
| Parker Moss | Executive Vice President of Corporate Development | 0 | N/A |
| Richard | Chief Business Officer | 0 | N/A |
| Sara Sherman | Vice President of Investor Relations | 0 | N/A |
| Caroline Rowland | Chief People Officer | 0 | N/A |
| John Overington | Chief Technology Officer | 0 | N/A |
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
